The latest headlines around AstraZeneca, from its £207b valuation to its multibillion dollar R&D and expansion plans, show how a single company’s choices on investment, geography, and pipeline risk can ripple across the wider pharmaceuticals and biotechnology sector. For investors, this news creates both potential opportunity and fresh questions about concentration in China, future drug exclusivity, and the impact of trial setbacks. This article looks at 3 large cap stocks from our Pharmaceutical and Biotechnology Stocks screener that appear positively exposed to these themes, helping you decide which stories might deserve a closer look next.

Krystal Biotech (KRYS)

Overview: Krystal Biotech is a commercial stage US biotechnology company that develops and sells genetic medicines, led by its gene therapy VYJUVEK for dystrophic epidermolysis bullosa, alongside a broad pipeline targeting eye disease, lung conditions such as cystic fibrosis and Alpha 1 antitrypsin deficiency, oncology, and aesthetic skin disorders.

Operations: Krystal Biotech generates all of its US$417.3m in revenue from the discovery, development, manufacturing and commercialization of genetic medicines in the United States.

Market Cap: US$10.8b

Krystal Biotech sits at the intersection of cutting edge gene therapy and rare disease care, which helps explain why its profitability metrics are already strong and earnings growth has outpaced much of the biotech sector. The company has one commercial product, VYJUVEK, supported by approvals in the US, EU, Japan and now the UK. It is using that cash flow to fund a packed pipeline in eye disease, lung disease and oncology that could gradually reduce its reliance on a single therapy. At the same time, a high P/E multiple, heavy dependence on VYJUVEK today, insider selling and ongoing R&D and reimbursement risks mean expectations are high and execution needs to stay tight.

Krystal Biotech’s early gene therapy success and high P/E suggest the market sees something big taking shape, but the real story sits in the analyst forecasts for Krystal Biotech and what happens if VYJUVEK is no longer the only pillar.

Natera (NTRA)

Overview: Natera is a diagnostics company that develops and commercializes genetic and molecular testing, from non-invasive prenatal and miscarriage tests to cancer-focused tools like its Signatera minimal residual disease blood test, Prospera transplant rejection test, and other assays that help doctors tailor treatment and monitor patients more precisely.

Operations: Natera generates about US$2.5b in revenue from the development and commercialization of molecular testing services, with the vast majority coming from the United States.

Market Cap: US$38.7b

Natera gives you exposure to one of the most closely watched areas in biotech, using its Signatera MRD platform and transplant tests like Prospera to turn cutting edge molecular diagnostics into everyday clinical tools. Recent wins, including EU IVDR certification, NCCN guideline support and Japan approval for Signatera in colorectal cancer, show how its technology is being written into real-world practice, even as the company is still working toward sustainable profitability and carries high external funding risk. With analysts highlighting revenue and earnings expectations and pointing to 2026 trial and reimbursement catalysts, the key question for investors is whether Natera’s R&D heavy model and premium valuation can be justified by the scale of adoption that may lie ahead.

Natera’s accelerating test adoption story and premium valuation leave a clear question: how far expectations can stretch before risk bites. Get the full picture in the analyst forecasts for Natera and what might shift that balance next

Neurocrine Biosciences (NBIX)

Overview: Neurocrine Biosciences is a US biopharmaceutical company that develops and sells treatments for central nervous system and endocrine disorders, led by INGREZZA for tardive dyskinesia and Huntington’s chorea, women’s health drugs like Orilissa and Oriahnn, and newer products such as CRENESSITY and adrenal insufficiency therapies ALKINDI and Efmody.

Operations: Neurocrine Biosciences generates about US$3.1b in revenue from the research, development, commercialization and sale of pharmaceuticals, almost entirely in the United States.

Market Cap: US$17.8b

Neurocrine Biosciences may appeal to investors who want exposure to CNS drugs with meaningful commercial traction today, along with a broad range of late stage programs in development. INGREZZA and CRENESSITY are central to its current portfolio, and the company is also committing capital to multiple Phase III trials in depression and schizophrenia, as well as earlier stage work in epilepsy and obesity. This approach aligns with a strategy of sustained R&D investment. At the same time, portfolio concentration in a few key products, rising R&D spending, pricing pressure and new borrowing through a US$1.0b credit facility introduce execution risk, particularly if any major study does not meet expectations or if payers take a tougher stance on reimbursement.

Neurocrine Biosciences is already booking meaningful CNS revenue, but the real story may lie in what comes next. See how the late stage pipeline could reshape expectations in the analyst forecasts for Neurocrine Biosciences

The three large cap stocks covered here are only a starting point, with our full Pharmaceutical and Biotechnology Stocks screener surfacing 18 more companies whose business models, balance sheets, and pipelines tell equally compelling stories through the Pharmaceutical and Biotechnology Stocks screener. Use Simply Wall St to identify, filter, and analyze the exact catalysts, risk profiles, and narratives that matter to you so you can focus on the highest conviction ideas within this part of the market.

Take Control of Your Investment Journey

If Krystal Biotech or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What You Might Be Missing?

Fresh stock ideas can move from quiet accumulation to full breakout before most investors notice. Use these hand picked lists while the data still matters, and consider acting while they are still relevant.

• Seek durable cash flows and solid footing by scanning a curated list of solid balance sheet and fundamentals (47 results), which is designed to keep fragile balance sheets out of your way.
• Look for potential yield opportunities before income-focused investors take notice by reviewing 9 dividend fortresses, built to highlight consistency, coverage, and balance sheet strength.
• Explore long term demand for critical materials by checking 30 best rare earth metal stocks, which focuses on producers that may become more important if supply tightens further.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.